BR112022017724A2 - Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos - Google Patents

Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos

Info

Publication number
BR112022017724A2
BR112022017724A2 BR112022017724A BR112022017724A BR112022017724A2 BR 112022017724 A2 BR112022017724 A2 BR 112022017724A2 BR 112022017724 A BR112022017724 A BR 112022017724A BR 112022017724 A BR112022017724 A BR 112022017724A BR 112022017724 A2 BR112022017724 A2 BR 112022017724A2
Authority
BR
Brazil
Prior art keywords
braf
kras
egfr
targets
inhibitors
Prior art date
Application number
BR112022017724A
Other languages
English (en)
Inventor
K Nyati Mukesh
Bridges Alexander
Christopher Rech Jason
Taylor Watch Brennan
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of BR112022017724A2 publication Critical patent/BR112022017724A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INIBIDORES DE EGFR, KRAS, BRAF E OUTROS ALVOS E USO DOS MESMOS. A presente invenção refere-se a compostos que são úteis no tratamento de câncer.
BR112022017724A 2020-03-05 2021-03-05 Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos BR112022017724A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985561P 2020-03-05 2020-03-05
PCT/US2021/020990 WO2021178741A1 (en) 2020-03-05 2021-03-05 Inhibitors of egfr, kras, braf, and other targets and use of the same

Publications (1)

Publication Number Publication Date
BR112022017724A2 true BR112022017724A2 (pt) 2022-10-18

Family

ID=77612748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017724A BR112022017724A2 (pt) 2020-03-05 2021-03-05 Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos

Country Status (11)

Country Link
US (1) US20230098205A1 (pt)
EP (1) EP4114386A4 (pt)
JP (1) JP2023515689A (pt)
KR (1) KR20220150358A (pt)
CN (1) CN115768423A (pt)
AU (1) AU2021230553A1 (pt)
BR (1) BR112022017724A2 (pt)
CA (1) CA3174538A1 (pt)
IL (1) IL296091A (pt)
MX (1) MX2022010977A (pt)
WO (1) WO2021178741A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN113164418A (zh) 2018-12-05 2021-07-23 米拉蒂治疗股份有限公司 组合疗法
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2022056307A1 (en) 2020-09-11 2022-03-17 Mirati Therapeutics, Inc. Crystalline forms of a kras g12c inhibitor
WO2022132200A1 (en) 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
CN119899194B (zh) * 2025-03-31 2025-06-24 浙江省人民医院 双环杂芳基类braf负变构调节剂及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547977A (en) * 1967-10-27 1970-12-15 Velsicol Chemical Corp Novel carbanilates
GB0701955D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
CA3091834A1 (en) * 2018-02-23 2019-08-29 The Regents Of The University Of Michigan Egfr dimer disruptors and use of the same

Also Published As

Publication number Publication date
EP4114386A1 (en) 2023-01-11
JP2023515689A (ja) 2023-04-13
MX2022010977A (es) 2022-12-02
US20230098205A1 (en) 2023-03-30
AU2021230553A1 (en) 2022-10-13
CN115768423A (zh) 2023-03-07
CA3174538A1 (en) 2021-09-10
IL296091A (en) 2022-11-01
WO2021178741A1 (en) 2021-09-10
KR20220150358A (ko) 2022-11-10
EP4114386A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
BR112022017724A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
BR112022017508A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
EA202190630A1 (ru) Способы комбинированной терапии
BR112023017763A2 (pt) Inibidores kras g12d
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
ECSP22012826A (es) Inhibidores de parp1
CY1125065T1 (el) Αναστολεις mcl-1
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
CY1121334T1 (el) Αναστολεας κινασης aurora a
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
EA202190749A1 (ru) Способы комбинированной терапии
MX382562B (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub).
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
CY1125158T1 (el) Συνθεσεις για την αγωγη καρκινου με εξαντληση αργινινης και ανοσο-ογκολογικους παραγοντες
BR112023014898A2 (pt) Quinolinas e azaquinolinas como inibidores de cd38
PH12022552347A1 (en) Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
MX2024003989A (es) Metodos de tratamiento del cancer y composiciones farmaceuticas de los mismos.
BR112022001985A2 (pt) Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina
EA201792286A1 (ru) Способы лечения рака
EA202091694A1 (ru) Ингибиторы pd-1/pd-l1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]